[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478536":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":47,"responsibleParty":69,"collaborators":32,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":32,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":50,"whyStopped":32,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"The Methodist Hospital Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","ACTIVE_COMPARATOR","Endocardial radiofrequency ablation of ventricular tachycardia",[13],"Procedure: Catheter ablation",{"label":15,"type":16,"description":17,"interventionNames":18},"Venous ethanol","EXPERIMENTAL","Endocardial radiofrequency ablation of ventricular tachycardia combined with venous ethanol ablation of the tachycardia substrate",[19,13],"Drug: Venous ethanol",[21,27],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol",[15],[26],"Alcohol",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"PROCEDURE","Catheter ablation","Endocardial catheter ablation of VT substrate",[9,15],null,[34],{"name":35,"affiliation":5,"role":36},"Miguel Valderrabano, MD","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Iris Melissa Alanis","CONTACT","7134416548","imalanis@houstonmethodist.org",{"name":44,"role":40,"phone":45,"phoneExt":32,"email":46},"Casey Kappenman","3462382367","cjkappenman@houstonmethodist.org",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Houston Methodist Hospital","RECRUITING","Houston","Texas","77030","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-95.36327,29.76328,{"lat":60,"lon":59},[63,67,68],{"name":64,"role":40,"phone":65,"phoneExt":32,"email":66},"Chinwe Ngumezi, RN","346-238-0290","ccngumezi@houstonmethodist.org",{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},{"name":35,"role":36,"phone":32,"phoneExt":32,"email":32},{"type":70,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100478536","phase-2-venous-ethanol-for-ventricular-tachycardia-100478536",false,"NCT05511246","Venous Ethanol for Ventricular Tachycardia","Venous Ethanol for Ischemic Left Ventricular Tachycardia","VELVET","Inclusion Criteria:\n\n* Male and female, ages of 18 and 85 years and with a prior ICD implant\n* Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis\u002Fthinning in the absence of a non-ischemic cause)\n* One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG\u002Fcardiac monitor\n* Patients deemed candidates for RF ablation of VT\n* Able and willing to comply with pre-, post-, and follow-up requirements\n* Willing to sign the informed consent\n\nExclusion Criteria:\n\n* Serum creatinine \\>1.5 mg\u002FdL, or creatinine clearance \\\u003C30 ml\u002Fmin\n* Left ventricular (LV) ejection fraction ≤10%\n* Mobile LV thrombus on echocardiography\n* Absence of vascular access to the LV\n* Disease process likely to limit survival to \\\u003C12 months\n* New York Heart Association class IV heart failure\n* Cardiac surgery within the past 2 months (unless VT was incessant),\n* Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG)\n* Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia)\n* Severe aortic stenosis or mitral regurgitation with a flail leaflet\n* Pregnancy\n* Unwilling or unable to provide informed consent\n* Covid-19 positive testing within 14 days of randomization procedure\n* Enrolled, or planning to get enrolled, in another research study during his\u002Fher participation on the Velvet trial","ALL","18 Years","85 Years",{"count":83,"type":84},156,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial",[90,91],"Ventricular Tachycardia","Ischemic Cardiomyopathy",[93,94,95,96],"Ventricular tachycardia","Coronary veins","Ethanol","Ablation","2026-03-25",{"date":99,"type":100},"2026-03-30","ACTUAL",{"date":102,"type":100},"2023-04-12",{"date":104,"type":84},"2028-12-12",{"name":5,"class":6},1]